Hepion Pharmaceuticals (HEPA) Proxy Filing summary

Executive summary

• Pharma Two B presented integrated Phase 2b and Phase 3 data on P2B001, showing efficacy and safety as a first-line, once-daily treatment for early-stage Parkinson's disease, with fewer side effects than existing therapies.

• P2B001 demonstrated significant improvements in UPDRS scores and was well-tolerated, with fewer sleep-related and dopaminergic adverse events compared to titrated pramipexole ER.

• Pharma Two B is progressing toward a merger with Hepion Pharmaceuticals, aiming for an NDA submission for P2B001 post-merger.

• The merger, approved by both companies' boards, is expected to close in Q4 2024, pending shareholder and regulatory approvals, and will result in Pharma Two B listing on Nasdaq as “PHTB.”

• Hepion has restructured to preserve capital, winding down its NASH clinical trial and focusing on maximizing shareholder value.

Voting matters and shareholder proposals

• Hepion shareholders are being asked to vote on the proposed merger with Pharma Two B and related matters at a special meeting.

• The SEC has declared effective the registration statement and proxy materials for the merger, which are being mailed to shareholders.

Board of directors and corporate governance

• The merger has received approval from the boards of directors of both Pharma Two B and Hepion.

• Directors and executive officers of both companies may be considered participants in the proxy solicitation for the merger.